Crestor RAPID (The Efficacy of RosuvAstatin for Korean Dyslipidemia PatIents With Diabetes)

To evaluate the efficacy of rosuvastatin in Korean dyslipidemia patients with diabetes

Completed

Looking for future studies?

Key information

Conditions

Dyslipidemia Diabetes Diabetes Mellitus Dyslipidemias Endocrine System Diseases Glucose Metabolism Disorders Lipid Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Seoul, Jongro-gu, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Hyperlipidemia patients who are prescribed with rosuvastatin 10mg, based on clinical grounds and fulfil the following criteria

Over 18 years of age
Diagnosed with DM based on fasting or post-load glucose data and/or clinical assessment by the clinician

Exclusion criteria

Patients already taking other hyperlipidemic agents
Patients who do not fulfil the indication criteria for statin therapy
Patients who do not have baseline and/or follow-up lipid data to verify the efficacy data

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

RAPID (Evaluating the Efficacy of RosuvAstatin for Korean Dyslipidemia PatIents With Diabetes in Real World Practice)

Acronym: RAPID

Important dates

Study start: 2007
Primary completion: 2007
Study completion: 2007
First posted: Sep 10, 2007
Registry last updated: Mar 30, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed